Differential cellular and molecular effects of butyrate and trichostatin a on vascular smooth muscle cells

Pharmaceuticals

Volumn 5, Issue 9, 2012, Pages 925-943

  Milton, Shirlette G ^a   Mathew, Omana P ^a   Yatsu, Frank M ^b   Ranganna, Kasturi ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Butyrate; Cyclin D1; HDAC; Proliferation; Trichostatin A; Vascular smooth muscle cells

Indexed keywords

BUTYRIC ACID; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE 3; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN D1 GENE; CYTOSTASIS; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RAT; TRANSCRIPTION REGULATION; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 84866539217     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph5090925     Document Type: Article

References (59)

1. Dzau, V.J.; Braun-Dullaeus, R.C.; Sedding, D.G. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat. Med. 2002, 8, 1249-1256.
2. Libby, P. Inflammation in atherosclerosis. Nature 2002, 420, 868-874.
3. Pons, D.; de Vries, F.R.; van den Elsen, P.J.; Heijmans, B.T.; Quax, P.H.; Jukema, J.W. Epigenetic histone acetylation modifiers in vascular remodeling: New targets for therapy in cardiovascular disease. Eur. Heart J. 2009, 30, 266-277.
4. Ranganna, K.; Yatsu, F.M.; Mathew, O.P. Insights into the pathogenesis and intervention of atherosclerosis. Vasc. Dis. Prev. 2006, 3, 375-390.
5. Ross, R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 1995, 57, 791-804.
6. Holmes, D.R., Jr. State of the art in coronary intervention. Am. J. Cardiol. 2003, 91, 50A-53A.
7. Ranganna, K.; Yousefipour, Z.; Yatsu, F.M.; Milton, S.G.; Hayes, B.E. Gene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation. Mol. Cell. Biochem. 2003, 254, 21-36.
8. Zhang, Q.J.; Goddard, M.; Shanahan, C.; Shapiro, L.; Bennett, M. Differential gene expression in vascular smooth muscle cells in primary atherosclerosis and in-stent stenosis in humans. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 2030-2036.
9. Ekström, T.J. Epigenetic control of gene expression. Biochim. Biophys. Acta 2009, 1790, 845-846.
10. Turunen, M.P.; Aavik, E.; Yla-Herttuala, S. Epigenetics and atherosclerosis. Biochim. Biophys. Acta 2009, 1790, 886-891.
11. Ranganna, K.; Yatsu, F.M.; Mathew, O.P. Emerging epigenetic therapy for vascular proliferative diseases. Available online: http://www.intechopen.com/articles/show/title/emerging-epigenetictherapy-for-vascular-proliferative-diseases/ (accessed on 22 August 2012).
12. Kristeleit, R.; Stimson, L.; Workman, P.; Aherne, W. Histone modification enzymes: Novel targets for cancer drugs. Expert Opin. Emerg. Drugs 2004, 9, 135-154.
13. Ranganna, K.; Yatsu, F.M.; Hayes, B.E. Butyrate, a small pleiotropic molecule with multiple cellular and molecular actions: Its role as an anti-atherogenic agent. Recent Res. Dev. Mol. Cell. Biochem. 2005, 2, 123-151.
14. Berni Canani, R.; di costanzo, M.; Leone, L. The epigenetic effects of butyrate: Potential therapeutic implications for clinical practice. Clin. Epigenetics 2012, 4, 4.
15. Seidel, C.; Schnekenburger, M.; Dicato, M.; Diederich, M. Histone deacetylase modulators provided by Mother Nature. Genes Nutr. 2012, 7, 357-367.
16. Bhalla, K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 2005, 23, 3971-3993.
17. Mathew, O.P.; Ranganna, K.; Yatsu, F.M. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells. Biomed. Pharmacother. 2010, 64, 733-740.
18. Cao, D.; Wang, Z.; Zhang, C.L.; Oh, J.; Xing, W.; Li, S.; Richardson, J.A.; Wang, D.Z.; Olson, E.N. Modulation of smooth muscle gene expression by association of histone acetyltransferases and deacetylases with myocardin. Mol. Cell. Biol. 2005, 25, 364-376.
19. Sahar, S.; Reddy, M.A.; Wong, C.; Meng, L.; Wang, M.; Natarajan, R. Cooperation of SRC-1 and p300 with NF-kB and CREB in angiotensin II-induced IL-6 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1528-1534.
20. Vinh, A.; Gaspari, T.A.; Liu, H.B.; Dousha, L.F.; Widdop, R.E.; Dear, A.E. A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J. Vasc. Res. 2008, 45, 143-152.
21. Waltregny, D.; Glénisson, W.; Tran, S.L.; North, B.J.; Verdin, E.; Colige, A.; Castronovo, V. Histone deacetylase HDAC8 associates with smooth muscle -actin and is essential for smooth muscle cell contractility. FASEB J. 2005, 19, 966-968.
22. Xu, X.; Ha, C.H.; Wong, C.; Wang, W.; Hausser, A.; Pfizenmaier, K.; Olson, E.N.; McKinsey, T.A.; Jin, Z.G. Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2355-2362.
23. Yan, Z.Q.; Yao, Q.P.; Zhang, M.L.; Qi, Y.X.; Guo, Z.Y.; Shen, B.R.; Jiang, Z.L. Histone deacetylases modulate vascular smooth muscle cell migration induced by cyclic mechanical strain. J. Biomech. 2009, 42, 945-948.
24. McDonald, O.G.; Wamhoff, B.R.; Hoofnagle, M.H.; Owens, G.K. Control of srf binding to carg boxchromatin regulates smooth muscle gene expression in vivo. J. Clin. Invest. 2006, 116, 36-48.
25. Okamoto, H.; Fujioka, Y.; Takahashi, A.; Takahashi, T.; Taniguchi, T.; Ishikawa, Y.; Yokoyama, M.; Trichostatin, A. An inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21 (WAF1). J. Atheroscler. Thromb. 2006, 13, 183-191.
26. Ranganna, K.; Yatsu, F.M.; Hayes, B.E.; Milton, S.G.; Jayakumar, A. Butyrate inhibits proliferation-induced proliferating cell nuclear antigen expression (PCNA) in rat vascular smooth muscle cells. Mol. Cell. Biochem. 2000, 205, 149-161.
27. Yamashita, Y.; Shimada, M.; Harimoto, N.; Rikimaru, T.; Shirabe, K.; Tanaka, S.; Sugimachi, K. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer 2003, 103, 572-576.
28. Jeon, H.G.; Yoon, C.Y.; Yu, J.H.; Park, M.J.; Lee, J.E.; Jeong, S.J.; Hong, S.K.; Byun, S.S.; Lee, S.E. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells. J. Urol. 2011, 186, 2084-2093.
29. Francisco, R.; Pérez-Perarnau, A.; Cortés, C.; Gil, J.; Tauler, A.; Ambrosio, S. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett. 2012, 318, 42-52.
30. Wetzel, M.; Premkumar, D.R.; Arnold, B.; Pollack, I.F. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J. Neurosurg. 2005, 103, 549-556.
31. Sherr, C.J.; Roberts, J.M. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13, 1501-1512.
32. Lundberg, A.S.; Weinberg, R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 1998, 18, 753-7561.
33. Dokmanovic, M.; Clarke, C.; Marks, P.A. Histone deacetylase inhibitors: Overview and perspectives. Mol. Cancer Res. 2007, 5, 981-989.
34. Lallemand, F.; Courilleau, D.; Sabbah, M.; Redeuilh, G.; Mester, J. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. Biochem. Biophys. Res. Commun. 1996, 229, 163-169.
35. Siavoshian, S.; Segain, J.P.; Kornprobst, M.; Bonnet, C.; Cherbut, C.; Galmiche, J.P.; Blottière, H.M. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: Induction of cyclin D3 and p21 expression. Gut 2000, 46, 507-514.
36. Davis, T.; Kennedy, C.; Chiew, Y.E.; Clarke, C.L.; DeFazio, A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 2000, 6, 4334-4342.
37. Vaziri, C.; Stice, L.; Faller, D.V. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 1998, 9, 465-474.
38. Li, C.; Liu, W.; Meng, F.; Huang, W.; Zhou, J.; Sun, H.; Feng, Y. Effect and comparison of sodium butyrate and trichostatin A on the proliferation/differentiation of K562. J. Huazhong Univ. Sci. Technol. Med. Sci. 2003, 23, 249-253.
39. Alao, J.P.; Stavropoulou, A.V.; Lam, E.W.-F.; Coombes, R.C.; Vigushin, D.M. Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. BMC Mol. Cancer 2006, 5, 8.
40. Jeon, H.G.; Yoon, C.Y.; Yu, J.H.; Park, M.J.; Lee, J.E.; Jeong, S.J.; Hong, S.K.; Byun, S.S.; Lee, S.E. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells. J. Urol. 2011, 186, 2084-2093.
41. Bajbouj, K.; Mawrin, C.; Hartig, R.; Schulze-Luehrmann, J.; Wilisch-Neumann, A.; Roessner, A.; Schneider-Stock, R. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J. Neurooncol. 2012, 107, 503-516.
42. Feng, P.; Ge, L.; Akyhani, N.; Liau, G. Sodium butyrate is a potent modulator of smooth muscle cell proliferation and gene expression. Cell Prolif. 1996, 29, 231-241.
43. Diehl, J.A.; Cheng, M.; Roussel, M.F.; Sherr, C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12, 3499-3511.
44. Takahashi-Yanaga, F.; Sasaguri, T. GSK-3β regulates cyclin D1 expression: A new target for chemotherapy. Cell. Signal. 2008, 20, 581-589.
45. Alt, J.R.; Cleveland, J.L.; Hannink, M.; Diehl, J.A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000, 14, 3102-3114.
46. Kaidanovich-Beilin, O.; Woodgett, J.R. GSK-3: Functional Insights from cell Biology and animal models. Front. Mol. Neurosci. 2011, 4, 40.
47. Yang, K.; Guo, Y.; Stacey, W.C.; Harwalkar, J.; Fretthold, J.; Hitomi, M.; Stacey, D.W. Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels. BMC Cell Biol. 2006, 7, 33.
48. Zou, Y.; Ewton, D.Z.; Deng, X.; Mercer, S.E.; Friedman, E. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J. Biol. Chem. 2004, 279, 27790-27798.
49. Ito, T. Role of histone modifications in chromatin dynamics. J. Biochem. 2007, 141, 609-614.
50. McManus, K.J.; Hendzel, M.J. The relationship between histone H3 phosphorylation and acetylation throughout the mammalian cell cycle. Biochem. Cell Biol. 2006, 84, 640-657.
51. Edmondson, D.G.; Davie, J.K.; Zhou, J.; Mirnikjoo, B.; Tatchell, K.; Dent, S.Y. Site-specific loss of acetylation upon phosphorylation of histone H3. J. Biol. Chem. 2002, 277, 29496-29502.
52. Eberlin, A.; Grauffel, C.; Oulad-Abdelghani, M.; Robert, F.; Torres-Padilla, M.E.; Lambrot, R.; Spehner, D.; Ponce-Perez, L.; Würtz, J.M.; Stote R.H.; et al. Histone H3 tails containing dimethylated lysine and adjacent phosphorylated serine modifications adopt a specific conformation during mitosis and meiosis. Mol. Cell Biol. 2008, 28, 1739-1754.
53. Ducasse, M.; Brown, M.A. Epigenetic aberrations and cancer. Mol. Cancer 2006, 5, 60.
54. Ramos, K.; Cox, L.R. Primary cultures of rat aortic endothelial and smooth muscle cells: I. An in vitro model to study xenobiotic-induced vascular cytotoxicity. In Vitro Cell. Dev. Biol. 1987, 23, 288-296.
55. Geisterfer, A.A.; Peach, M.J.; Owens, G.K. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. 1988, 62, 749-756.
56. Ranganna, K.; Yatsu, F.M. Inhibition of platelet derived growth factor BB-induced expression of glyceraldehyde-3-phosphate dehydrogenase by sodium butyrate in rat vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 3420-3427.
57. Fu, M.; Wang, C.; Li, Z.; Sakamaki, T.; Pestell, R.G. Cyclin D1: Normal and abnormal functions. Endocrinology 2004, 145, 5439-5447.
58. Marampon, F.; Casimiro, M.C.; Fu, M.; Powell, M.J.; Popov, V.M.; Lindsay, J.; Zani, B.M.; Ciccarelli, C.; Watanabe, G.; Lee R.J.; et al. Nerve growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kB. Mol. Biol. Cell 2008, 19, 2566-2578.
59. Fu, M.; Wang, C.; Rao, M.; Wu, X.; Bouras, T.; Zhang, X.; Li, Z.; Jiao, X.; Yang, J.; Li A.; et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J. Biol. Chem. 2005, 280, 29728-29742.